wockhardt investor presentation may 2015
TRANSCRIPT
Wockhardt Limited
Investor Presentation By
Dr. Murtaza Khorakiwala Managing Director
Q4FY15 & FY14-15
Safe Harbor Statement
• Except for historical information contained herein, statements in this communication, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute “forward looking statements”. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Wockhardt Limited does not undertake any obligation to update forward looking statements to reflect events or circumstances after the date thereof.
Investor Presentation May 2015 2
Introduction to Wockhardt Key Business Dynamics
ROW operations Wockhardt Direct operations
USA
UK, Ireland, France, Switz.
India
Mexico
Wockhardt Today
Investor Presentation May 2015 4
Direct Operations
in India, USA
and Europe
8600 Associates employed in 21
countries
UK Ireland
Wockhardt Today
Investor Presentation May 2015 5
12
Manufacturing Locations globally
Ankleshwar Daman (2 Plants)
Aurangabad (5 Plants)
Baddi
Chicago
Formulations APIs
9 sites in India
Wockhardt Today
Investor Presentation May 2015 6
3 R&D Centers
worldwide
USA / UK & India
Key Business Update
Key Business Update
Investor Presentation May 2015 8
UK MHRA lifted Statement of Non Compliance from L1 Facility and have also restored EU GMP certification of Kadaiya facility.
MGP Facility:- 483 response was found satisfactory from US FDA. US FDA conducted inspection in L1 & Waluj facilities & observed on going improvement
in company's efforts towards compliance.
Obtained QIDP status from US FDA for 2 of its drugs WCK 771 & WCK 2349 for New Drug
Discovery program in Anti-infective research in FY15. Also obtained QIDP status for its third NCE product WCK 4873 during this month. QIDP status allows for fast track review by US FDA and also grants a five year extensions to the drug patents in USA. Wockhardt is the only Indian company to receive QIDP status for its NCE products.
Filed for 267 patents during the Year taking the cumulative filings to 2268 and has been granted 82 patents during the Year taking the cumulative patents granted to 341.
Regulatory Update
Research Update
Q4FY15 Results
Sales – Growth of 4% over Q4FY14
Investor Presentation May 2015 10
Rs.crore
Growth of 4% in Q4FY15 over Q4FY14
EBITDA – Growth of 11% over Q4FY14
Investor Presentation May 2015 11
Rs.crore
Growth of 11% in Q4FY15 over Q4FY14
PAT – Decline of 55% over Q4FY14
Investor Presentation May 2015 12
Rs.crore
De-growth of 55% in Q4FY15 over Q4FY14
FY 14-15 Results
Sales – Decline of 7% over FY 13-14
Investor Presentation May 2015 14
Rs.crore
Decline of 7% in FY 14-15 over FY 13-14
EBITDA – Declines by 16% over FY 13-14
Investor Presentation May 2015 15
Rs.crore
Declines by 16% in FY 14-15 over FY 13-14
PAT – Declines by 52% over FY 13-14
Investor Presentation May 2015 16
Rs.crore
Declines by 52% in FY 14-15 over FY 13-14
Research – 11.5% of Sales in FY14-15
Investor Presentation May 2015 17
US Business
Investor Presentation May 2015 18
• Declines by 21% (22% in $ terms)
over Q4FY14.
• Declines by 49% (51% in $ terms)
over FY 13-14.
• During the year 14 ANDA’s filed &
cumulative ANDA’s pending for
approval is 69. 2,150 1,087
-
500
1,000
1,500
2,000
2,500
FY 13-14 FY 14-15
USA
Rs.
cr.
$364
$179
EU Operations UK Operations
• 8 New Approvals received in FY 14-15.
• 11 New Fillings done in FY 14-15 , 1 in Q4FY15.
• UK operation Grows by 36% (grows by 34% £ terms) in
Q4FY15. Grows by 46% (35% in £ terms) in FY 14-15.
• Among top 5 generic company.
Investor Presentation May 2015 19
Ireland Operations
• Ireland Declines by 11% (6% in € terms) in Q4FY15.
Decline by 10% (11% in € terms) in FY 14-15.
964 1,405 100
300
500
700
900
1,100
1,300
1,500
FY 13-14 FY 14-15
UK
Rs.
cr.
£ 104
£ 141
176 158 -
50
100
150
200
250
FY 13-14 FY 14-15
Ireland
Rs.
cr.
€ 22 € 20
India & Emerging Markets • Total Emerging Markets (Including India)
Grows by 26% for Q4FY15. Grows by 19%
for FY 14-15.
• India Business Grows by 46% for Q4FY15
and Grows by 24% during FY 14-15.
• 2 new products in Q4FY15 and 42 new
products launched in FY 14-15 in India.
• Emerging Market operations declined by
25% in Q4FY15 and grew by 3% during FY
14-15.
Investor Presentation May 2015 20
998 India
1235 India
302 Em
312 Em
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
FY 13-14 FY 14-15
India & Emerging Markets (Em)
Rs.
cr.
Investor Presentation May 2015 21
For investor updates and communication please visit www.wockhardt.com
For Information please contact Arun Khatanhar Tel.: +91 22 71596228 [email protected]